cyclacel.com (BGMS): Operating Margin

Official company branding of Cyclacel (BGMS)

Bio Green Med Solution Inc develops targeted cell cycle inhibitors for the precise destruction of tumors. The operating margin trend on the GURU.Markets chart visualizes the impact of patents on asset value, while the -101.40 figure characterizes this level. However, the high cost of clinical trials leads to a liquidity deficit and the rapid depletion of the issuer's working capital.

BGMS - Bio Green Med Solution Inc. Operating Profit Rate over the range 09/13/2025 - 11/19/2026

Bio Green Med Solution Inc - analytical breakdowns and key metrics (BGMS)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Fundamental company analysis:BGMS, Cyclacel Pharmaceuticals
Finished products of Cyclacel

Fundamental analysis of this metric minimizes capital freeze risks by identifying the efficiency of chemical supply cost management for cancer therapy and the diversification of research centers. The ratio of operating profit to revenue, reflected through the calculated operating margin, demonstrates the ability of Bio Green Med Solution Inc. (BGMS) to generate income from its core business before accounting for tax and interest obligations.